Related Articles
Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy
Sulforaphane has an additive anticancer effect to FOLFOX in highly metastatic human colon carcinoma cells
Low expression of PKCĪ± and high expression of KRAS predict poor prognosis in patients with colorectal cancer
Multidrug resistance-associated protein 2 determines the efficacy of cisplatin in patients with hepatocellular carcinoma
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI